Zenas BioPharma, Inc.: retained earnings or deficit
Retained earnings or deficit for Zenas BioPharma, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Zenas BioPharma, Inc. financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2023-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | -765,128,000 | USD | 2026-03-16 | 10-K · 0001104659-26-027964 |
| At date | 2024-12-31 | -387,391,000 | USD | 2026-03-16 | 10-K · 0001104659-26-027964 |
| At date | 2023-12-31 | -230,403,000 | USD | 2025-03-11 | 10-K · 0001558370-25-002631 |
Related financial histories
- Zenas BioPharma, Inc.: total assets
- Zenas BioPharma, Inc.: total liabilities
- Zenas BioPharma, Inc.: stockholders equity
- Zenas BioPharma, Inc.: cash and cash equivalents
- Zenas BioPharma, Inc.: net income or loss
- Zenas BioPharma, Inc.: operating cash flow
- Zenas BioPharma, Inc.: capital expenditure payments
- Zenas BioPharma, Inc.: revenue
- Zenas BioPharma, Inc.: contract revenue excluding tax
- Zenas BioPharma, Inc.: financing cash flow
- Zenas BioPharma, Inc.: investing cash flow
- Zenas BioPharma, Inc.: basic weighted-average shares
- Zenas BioPharma, Inc.: diluted weighted-average shares
- Zenas BioPharma, Inc.: basic earnings per share
- Zenas BioPharma, Inc.: diluted earnings per share
- Zenas BioPharma, Inc.: income tax expense or benefit
- Zenas BioPharma, Inc.: net property, plant and equipment
- Zenas BioPharma, Inc.: share-based compensation expense
- Zenas BioPharma, Inc.: operating income or loss
- Zenas BioPharma, Inc.: current assets
- Zenas BioPharma, Inc.: current liabilities
- Zenas BioPharma, Inc.: current accounts payable
- Zenas BioPharma, Inc.: operating expenses
- Zenas BioPharma, Inc.: research and development expense
Inspect the source
- Entity
- Zenas BioPharma, Inc. / CIK 0001953926
- Captured
- 2026-09-21T17:38:00.180Z
- SEC response SHA-256
bd79c6d0fc0258ae5600e6e4156de5e3d36c0693f6d1939f3fb6019844471737
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001953926.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))